Q2/2024 6/30/2024 EPS -0.580 ZacksConsensus -0.690 ActVsEst 0.110 - Beat
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at HC Wainwright from $54.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswire
KYMR
Earnings
- 2/27/25 - Miss
KYMR
Sec Filings
- 3/3/25 - Form 4
- 3/3/25 - Form 4
- 3/3/25 - Form 4
- KYMR's page on the SEC website